SG
SGHT.US Sight Sciences Inc
- Market cap
- USD 583M
- P/E
- -
- P/B
- 11.98x
- ROE
- -65.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SGHT.US undervalued?
Graham numberThe Graham number of Sight Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sight Sciences Inc fundamental analysis
No fundamental analysis for Sight Sciences Inc yet.
Sight Sciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sight Sciences Inc
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce…
Full company profileSight Sciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sight Sciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 7.53M | 23.3M | 27.6M | 49.0M | 71.3M | 81.1M | 79.9M | 77.4M | 90.7M |
| Gross Profit | 5.19M | 16.8M | 18.4M | 40.3M | 59.0M | 69.2M | 68.3M | 66.7M | 79.7M |
| Operating Income | -14.3M | -24.0M | -32.2M | -51.5M | -84.0M | -57.3M | -50.5M | -37.1M | -29.9M |
| EBITDA | -14.2M | -23.6M | -31.7M | -57.8M | -81.0M | -49.4M | -45.9M | -32.8M | -28.9M |
| Net Income | -14.3M | -25.9M | -34.7M | -63.0M | -86.2M | -55.5M | -51.5M | -38.4M | -32.3M |
| EPS | -0.44 | -0.77 | -0.74 | -1.33 | -1.80 | -1.14 | -1.03 | -0.74 | -0.59 |
| Balance Sheet | |||||||||
| Total Assets | 8.09M | 30.7M | 72.8M | 280M | 213M | 167M | 143M | 115M | 105M |
| Total Liabilities | 37.1M | 85.4M | 162M | 48.1M | 53.0M | 46.4M | 55.3M | 51.4M | 55.8M |
| Shareholders' Equity | -29.0M | -54.7M | -88.8M | 232M | 160M | 120M | 87.5M | 63.9M | 49.1M |
| Cash & Short-term Investments | 4.24M | 21.2M | 61.5M | 261M | 185M | 138M | 120M | 92.0M | 77.4M |
| Total Debt | 34.2M | 13.9M | 32.5M | 33.2M | 35.0M | 35.4M | 40.4M | 40.8M | 42.1M |
| Cash Flow | |||||||||
| Operating Cash Flow | -14.5M | -25.0M | -32.2M | -52.5M | -76.0M | -47.2M | -22.4M | -29.7M | -20.1M |
| Capital Expenditure | 570K | 672K | 953K | 813K | 970K | 791K | 385K | 224K | 196K |
| Free Cash Flow | -15.0M | -25.7M | -33.1M | -53.4M | -76.9M | -48.0M | -22.7M | -29.9M | -20.3M |
| Ratios | |||||||||
| ROE | - | - | - | -27.1% | -53.9% | -46.2% | -58.8% | -60.1% | -65.8% |
| ROA | -176.6% | -84.2% | -47.7% | -22.5% | -40.5% | -33.3% | -36.1% | -33.3% | -30.8% |
| Net Profit Margin | -189.8% | -110.8% | -125.5% | -128.6% | -120.9% | -68.5% | -64.5% | -49.7% | -35.6% |
| Debt to Equity | - | - | - | 0.14x | 0.22x | 0.29x | 0.46x | 0.64x | 0.86x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sight Sciences Inc dividends
Sight Sciences Inc has not paid dividends in the last 8 fiscal years.
Who owns Sight Sciences Inc
- Insiders 19.63%
- Institutions 53.88%
- Public & others 26.49%
- Shares outstanding 55.6M
- Free float 36.0M
Top funds holding SGHT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.14M | 2.06% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.01M | 1.81% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 430K | 0.77% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 361K | 0.65% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 229K | 0.41% | +1.47% | Sep 2026 |
| iShares U.S. Small-Cap Eq Fac ETF | 225K | 0.40% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 208K | 0.37% | +0.23% | Oct 2026 |
| Invesco Dorsey Wright SmallCap Momt ETF | 191K | 0.34% | -0.54% | Oct 2026 |
| Royce Small-Cap Growth Svc | 179K | 0.32% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 176K | 0.32% | +1.52% | Sep 2026 |
| iShares Micro-Cap ETF | 120K | 0.22% | 0.00% | Oct 2026 |
| Dimensional US Small Cap ETF | 102K | 0.18% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 97.4K | 0.18% | 0.00% | Sep 2026 |
| Lazard Baylight US Sm Cap Eq WW Dist EUR | 96.7K | 0.17% | +0.60% | Jul 2026 |
| CREF Total Global Stock Account R3 | 96.5K | 0.17% | -4.95% | Sep 2026 |
| DFA US Micro Cap I | 83.7K | 0.15% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 71.6K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 71.4K | 0.13% | +11.56% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 65.3K | 0.12% | 0.00% | Oct 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 57.7K | 0.10% | +190.45% | Jun 2026 |
Top institutions holding SGHT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Long Focus Capital Management, LLC | 3.84M | 6.92% | +6.96% | Jun 2026 |
| BlackRock Inc | 3.08M | 5.55% | +8.87% | Jun 2026 |
| Pathstone Holdings LLC | 1.68M | 3.02% | -29.96% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.57M | 2.83% | +8.34% | Jun 2026 |
| B Group, Inc | 970K | 1.75% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 959K | 1.72% | +4.71% | Jun 2026 |
| Acadian Asset Management LLC | 844K | 1.52% | +4.65% | Sep 2026 |
| State Street Corp | 835K | 1.50% | +0.05% | Jun 2026 |
| AQR Capital Management LLC | 398K | 0.72% | +187.01% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 371K | 0.67% | -3.33% | Sep 2026 |
| Qube Research & Technologies | 363K | 0.65% | -27.10% | Jun 2026 |
| Northern Trust Corp | 344K | 0.62% | +3.39% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 338K | 0.61% | +3.21% | Jun 2026 |
| D. E. Shaw & Co LP | 280K | 0.50% | -10.09% | Jun 2026 |
| Charles Schwab Investment Management Inc | 276K | 0.50% | -1.09% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 272K | 0.49% | +9.40% | Jun 2026 |
| Panagora Asset Management Inc | 263K | 0.47% | +35.21% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 256K | 0.46% | +6.29% | Jun 2026 |
| Squarepoint Ops LLC | 218K | 0.39% | -34.26% | Jun 2026 |
| Citadel Advisors Llc | 216K | 0.39% | +59.87% | Jun 2026 |
Sight Sciences Inc company profile
- Company name
- Sight Sciences Inc
- Ticker
- SGHT.US
- Exchange
- USA Stocks
- Listed since
- Jul 15, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 186
- Fiscal year end
- December
- Address
- 4040 Campbell Avenue, Menlo Park, CA, United States, 94025
- Phone
- 877 266 1144
- Website
- sightsciences.com
About Sight Sciences Inc
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Sight Sciences Inc management
10- Mr. Paul BadawiCo-Founder, President, CEO & Director · born 1976
- Ms. Alison Perry BauerleinChief Operating Officer · born 1981
- Dr. David Badawi M.D.Co-Founder, CTO & Director · born 1971
- Mr. James RodbergCFO & Treasurer · born 1984
- Mr. Steve R. Tamayo Jr.VP and Chief Ethics & Compliance Officer
- Mr. Kashif Rashid J.D.Chief Legal Officer & Corporate Secretary · born 1973
- Ms. Kelly VaupelVice President of Marketing & Commercial Strategy, Interventional Glaucoma
- Ms. Sonia ClarkVice President of People
- Mr. Brenton TaylorExecutive Vice President of Operations and R&D · born 1981
- Ms. Kelly PetrucciSenior Vice President of Market Access & Strategy